Comparative Pharmacology
Head-to-head clinical analysis: BOSULIF versus EXKIVITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSULIF versus EXKIVITY.
BOSULIF vs EXKIVITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that targets BCR-ABL kinase, as well as SRC family kinases. It inhibits the phosphorylation of tyrosine residues in proteins involved in the BCR-ABL signaling pathway, thereby inhibiting cell proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemia cells.
Irreversible tyrosine kinase inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, and specifically inhibits EGFR T790M and C797S resistance mutations, with less activity against wild-type EGFR.
400 mg orally once daily with food.
150 mg orally once daily with or without food.
None Documented
None Documented
The terminal elimination half-life is approximately 22.5 hours (range 15-34 hours) following a 500 mg oral dose. This supports once-daily dosing, with steady-state achieved within 15 days.
Terminal elimination half-life is approximately 48 hours, supporting once-daily dosing for systemic exposure.
Primarily fecal (approximately 85% of the administered dose), with renal excretion accounting for less than 1% as unchanged drug and 3% as metabolites. Biliary excretion is a significant route for elimination of unchanged drug and metabolites.
Primarily hepatic metabolism with biliary excretion; 91% of total recovered in feces (30% as unchanged drug), <1% in urine.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor